Clinical Features of Chinese Coronary Heart Disease Patients with Chronic Kidney Disease

Figures & data

Table 1.  Clinical features of participants with CHD in different CKD stages.

Variables	eGFR ≥ 60 (CKD stages 1 and 2, N = 1694)	30 ≤ eGFR < 60 (CKD stage 3, N = 738)	eGFR < 30 (CKD stages 4 and 5, N = 77)	p-Value
Age (years old)	61.66 ± 10.16	71.89 ± 7.78	75.51 ± 12.00	<0.001
Sex [male, N (%)]	1223 (72.2)	371 (50.3)	36 (46.8)	<0.001
Smoking habit [N (%)]	336 (26.1)	56 (9.4)	6 (9.4)	<0.001
FBG (mmol/L)	5.88 ± 2.27	5.96 ± 2.60	6.71 ± 3.67	0.02
HS-CRP (mg/L)	5.50 ± 10.58	8.81 ± 20.06	18.31 ± 48.40	<0.001
TC (mmol/L)	4.83 ± 1.30	4.89 ± 1.38	4.76 ± 1.30	0.51
LDL (mmol/L)	2.88 ± 0.98	2.92 ± 1.06	2.96 ± 1.34	0.64
SBP (mm Hg)	130.2 ± 18.8	132.5 ± 18.3	141.0 ± 23.6	<0.001
DBP (mm Hg)	78.6 ± 10.6	76.9 ± 10.7	80.4 ± 13.0	0.001
Ischemic stroke [N (%)]	178 (10.6)	120 (16.3)	14 (18.4)	<0.001
DM [N (%)]	380 (22.5)	191 (26.0)	26 (33.8)	<0.001
PAD [N (%)]	193 (16.7)	152 (29.2)	15 (31.3)	<0.001
Triple vessel disease [N (%)]	358 (42.3)	155 (49.5)	15 (55.6)	0.01

Table 2.  Cardiovascular risk factors in patients with CHD after 6 weeks.

Variables	eGFR ≥ 60 (CKD stages 1 and 2, N = 1694)	30 ≤ eGFR < 60 (CKD stage 3, N = 738)	eGFR < 30 (CKD stages 4 and 5, N = 77)	p-Value
HS-CRP after 6 weeks (mmol/L)	3.70 ± 13.29	3.95 ± 4.53	46.28 ± 78.24	<0.001
FBG after 6 weeks (mmol/L)	5.64 ± 1.79	5.89 ± 2.32	6.72 ± 4.38	0.03
LDL after 6 weeks (mmol/L)	2.43 ± 0.72	2.55 ± 0.83	2.77 ± 0.82	0.03
SBP after 6 weeks (mm Hg)	126.2 ± 18.0	128.9 ± 18.1	137.1 ± 23.0	<0.001
DBP after 6 weeks (mm Hg)	73.8 ± 10.6	77.7 ± 10.7	79.3 ± 12.9	<0.001

Table 3.  Odds ratios and confidence intervals of risk factors correlated with renal dysfunction (eGFR < 60 mL/min/1.73 m²) in CHD patients.

Risk factors	Odds ratio	95% Confidence interval
Older age (>70 years old)	21.30	1.47–309.59
Sex (female)	51.08	6.76–483.14
Hypertension	1.17	0.75–1.71
DM	1.27	0.86–2.02
HS-CRP	1.05	0.74–1.76
Smoking habit	1.02	0.69–1.43
Ischemic stroke	1.15	0.72–1.62

Figure 1.  Cardiovascular risk factor control rate in CHD patients at baseline and after 6-week therapy were classified into three groups according to eGFR: ≥60 mL/min/1.73 m² (CKD stage 1–2), <30 mL/min/1.73 m² (CKD stage 4–5), ≥30 mL/min/1.73 m², and <60 mL/min/1.73 m² (CKD stage 3). Control rate of SBP and DBP (SBP < 125 mm Hg, DBP < 75 mm Hg) was poorer as CKD stage was more severe at baseline (40.5% vs. 33.3% vs. 25.3%, p < 0.001; 35.7% vs. 41.0% vs. 30.7%, p = 0.02). Control rate of FBG and LDL (FBG < 6.1 mmol/L, LDL < 2.6 mmol/L) was not significantly different in patients with different CKD stages at baseline (72.6% vs. 73.3% vs. 64.8%, p = 0.31; 40.9% vs. 40.2% vs. 44.7%, p = 0.75). SBP and DBP control rate was poorer as CKD stage was more severe after 6-week therapy (43.8% vs. 36.2% vs. 30.7%, p < 0.001; 48.5% vs. 41.7% vs. 32.0%, p < 0.001). Control rate of FBG and LDL was also poorer as CKD stage was more severe after 6-week therapy (78.2% vs. 73.2% vs. 55.0%, p = 0.02; 62.0% vs. 55.8% vs. 37.5%, p = 0.03).